Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.
Corporate Profile
Press Releases
November 14th, 2024
The New Patent Covers ENA-001 Methods of Treating Respiratory Depression Caused by Propofol, a Widely Used, Centrally Acting Anesthetic.
September 24th, 2024
The study will consist of utilizing both Enalare’s new Intramuscular formulation (IM), developed with funding provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, as well as an intravenous formulation (IV) via a bolus injection.
September 10th, 2024
This supplemental funding expands the 2022 contract, which now could provide up to $55.8 million to support the development of ENA-001.
February 15th, 2024
The article entitled “Reversal of Propofol-induced Depression of the Hypoxic Ventilatory Response by BK-channel Blocker ENA-001: A Randomized Controlled Trial” is based on a clinical study conducted under the direction of Albert Dahan, MD, PhD, a renowned global leader in the field of breathing control mechanisms, at the Leiden University Medical Center, the Netherlands.
Publications
Maarten van Lemmen, B.Sc., Jeffrey Florian, Ph.D., Zhihua Li, Ph.D., Monique van Velzen, Ph.D., Eveline van Dorp, M.D., Ph.D., Marieke Niesters, M.D., Ph.D., Elise Sarton, M.D., Ph.D., Erik Olofsen, Ph.D., Rutger van der Schrier, M.D., David G. Strauss, M.D., Ph.D., Albert Dahan, M.D., Ph.D.
Thomas L. Miller, Ph.D., Lynn M. Raab, MD, Thomas H. Shaffer, MS.E., Ph.D, Alfred Schweikert, Ph.D., RAC, Frank Diana, Ph.D., Prem Fort, MD, Alana S. Frum, LVTg, RVTg, BASVT, Joseph Pergolizzi, Jr., MD, Robert B. Raffa, Ph.D.
Margot Roozekrans, M.D., Rutger van der Schrier, M.D., Pieter Okkerse, M.D., Justin Hay, Ph.D., James F. McLeod, M.D., Albert Dahan, M.D., Ph.D
Joseph F. Cotten, M.D., Ph.D.
Francis J. Golder, Matthew M. Hewitt, James F. McLeod
Rutger van der Schier, Margot Roozekrans, Monique van Velzen, Albert Dahan and Marieke Niesters
J. F. McLeod, J. M. Leempoels, S. X. Peng, S. L. Dax, L. J. Myers and F. J. Golder
Corporate Info
BARDA Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures Division
Hear from our KOL, Dr. Eugene Vortsman
Northwell Health System Practicing Emergency Medicine Specialist
Hear from our KOL, Dr. TJ Gan
Stony Brook University Professor of and Chair, Department of Anesthesiology
Events
September 19th-21st, 2024
Enalare Therapeutic Presents at the American Society for Enhanced Recovery and Perioperative Medicine 2024
Resources
- Are opioid receptor antagonists adequate for “Opioid” overdose in a changing reality?
- History of Respiratory Stimulants
- Commentary: New Complications Make Treatment of “Opioid” Overdose Challenging
- Commentary: “Ockham’s Razor” Doesn’t Apply to “Opioid” Overdose Death
- Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial
- The Polysubstance Overdose-Death Crisis
- Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic
- The problem of postoperative respiratory depression